|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/36 | |
| A61K 38/48 | |||
| A61P 7/04 |
| (11) | Patento numeris | 2624859 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11761051.9 |
| Europos patento paraiškos padavimo data | 2011-09-19 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-08-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-03-01 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/066241 |
| Data | 2011-09-19 |
| (87) | Numeris | WO 2012/045569 |
| Data | 2012-04-12 |
| (30) | Numeris | Data | Šalis |
| 390224 P | 2010-10-06 | US |
| (72) |
LOVGREN, Ann, SE
HANSSON, Kenny, SE
|
| (73) |
Medimmune Limited,
Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH,
GB
|
| (54) | FACTOR II ALONE OR IN COMBINATION WITH FURTHER FACTORS FOR TREATMENT OF IMPAIRED HAEMOSTASIS ASSOCIATED WITH DILUTIONAL COAGULOPATHY |
| FACTOR II ALONE OR IN COMBINATION WITH FURTHER FACTORS FOR TREATMENT OF IMPAIRED HAEMOSTASIS ASSOCIATED WITH DILUTIONAL COAGULOPATHY |